Company news
Microbot Medical Inc. (NASDAQ:MBOT) news
Microbot Medical Inc. news releases on 6ix. Latest, Jun 17, 2025: Microbot Medical Strengthens Global IP Portfolio with Newly Granted Patent in China
Press releases — page 2
Microbot Medical Strengthens Global IP Portfolio with Newly Granted Patent in China
June 17, 2025
Microbot Medical Continues to Strengthen Commercial Capabilities in Preparation for the anticipated Q3 2025 Launch of its LIBERTY® Endovascular Robotic System
June 9, 2025
Microbot Medical Selected for Preliminary Inclusion to Russell Microcap® Index
June 5, 2025
Microbot Medical® Bolsters Commercial Leadership Team with the Addition of Experienced Healthcare Officers
April 23, 2025
Microbot Medical® Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System
April 9, 2025
REMINDER: Microbot Medical Announces Data from the Company’s ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Annual Meeting
April 1, 2025
Microbot Medical Appoints Seasoned Endovascular Sales Executive to Lead its U.S. Sales Activities for LIBERTY® Endovascular Robotic System
March 4, 2025
Robotic Telesurgery Data from Collaboration with Corewell Health™ Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting
February 25, 2025
Microbot Medical Closes $13 Million Registered Direct Offering
February 10, 2025
Microbot Medical Announces $13 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
February 9, 2025
Microbot Medical® Announces Late-Breaking Abstract Acceptance at the Society of Interventional Radiology Annual Meeting
February 3, 2025
Microbot Medical® Strengthens Its Management Team in Support of the Anticipated Commercial Launch of LIBERTY®
January 20, 2025
Microbot Medical® Strengthens Its Commercial Capabilities with the Addition of David J. Wilson to the Board of Directors
January 12, 2025
Microbot Medical Closes $8.6 Million Registered Direct Offering
January 9, 2025
Microbot Medical Announces $8.6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
January 7, 2025
Microbot Medical Raises a Total of Approximately $11.8 Million in Gross Proceeds from Registered Direct Offering and Previously Announced ATM Facility
January 6, 2025
Microbot Medical Announces $7 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
January 5, 2025
Microbot Medical® Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY®
December 29, 2024
Microbot Medical® Announces FDA Submission for the Commercialization of the LIBERTY® Endovascular Robotic System
December 9, 2024
Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025
October 14, 2024
Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up
September 29, 2024
Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System
September 16, 2024
Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System
August 21, 2024
Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization
August 12, 2024
Microbot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center
July 17, 2024
Microbot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial
July 8, 2024
Microbot Medical Enrolled the First Patient in its Pivotal Human Clinical Trial
July 7, 2024
Microbot Medical Partners with Baptist Hospital of Miami to Participate in its Pivotal Human Clinical Trial
July 2, 2024
Microbot Medical Partners with Brigham and Women's Hospital for Its Pivotal Human Clinical Trial
June 19, 2024
Microbot Medical Announces Brigham and Women's Hospital as a Site for its Pivotal Human Clinical Trial
June 16, 2024
Microbot Medical Announces Closing of $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
June 3, 2024
Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial
June 2, 2024
Microbot Medical Announces $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
June 2, 2024
Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™
April 28, 2024
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US
February 4, 2024
Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters
January 29, 2024
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study
January 17, 2024
Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
December 28, 2023
Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met
December 27, 2023
Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY® Endovascular Robotic Surgical System for Telerobotic
December 13, 2023
Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical Study
December 6, 2023
Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial Activities
November 20, 2023
Microbot Medical Granted Registered Trademark from The U.S. Patent and Trademark Office
November 7, 2023
Microbot Medical Reveals Successful Short Term Follow Up Outcomes from its Pivotal Pre-Clinical Study
October 30, 2023
Microbot Medical Received Confirmation for the Commencement of Its CE Mark Approval Process During the First Half of 2024
October 23, 2023
Microbot Medical Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against Company
October 18, 2023
Microbot Medical Announces Successful Initial Outcomes from Its Pivotal Pre-Clinical Study with the LIBERTY® Robotic Surgical System
October 16, 2023
Microbot Medical Engages CRO to Support its Upcoming U.S. Pivotal Clinical Trial
September 26, 2023
Microbot Medical Strengthens Its Position Among US Interventional Radiologists by Appointing Professor Francois H. Cornelis to Its Scientific Advisory Board
August 9, 2023
Microbot Medical Engaging with a Leading Notified Body to Advance CE Mark for Sales in Europe
July 24, 2023